SM 04690

Drug Profile

SM 04690

Alternative Names: SM-04690

Latest Information Update: 22 Jul 2017

Price : $50

At a glance

  • Originator Samumed
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Clinical Phase Unknown Intervertebral disc degeneration

Most Recent Events

  • 20 Jun 2017 Samumed completes a phase II trial in Osteoarthritis in USA
  • 14 Jun 2017 Efficacy data from a phase II trial in Osteoarthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR)
  • 01 Apr 2017 Samumed initiates a phase II trial for Osteoarthritis in USA (NCT03122860)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top